Sarepta downgraded to Market Perform from Outperform at JMP Securities JMP Securities downgraded Sarepta due to valuation and expectations pivotal data and approval of its Duchenne Muscular Dystrophy drug will take longer than expected.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Nebraska Medical Center not naming Ebola drug, The Street reports Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link